Comparative Pharmacology
Head-to-head clinical analysis: CEDAX versus CEFAZOLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEDAX versus CEFAZOLIN.
CEDAX vs Cefazolin
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftibuten is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP 3, thereby inhibiting peptidoglycan cross-linking and leading to cell lysis.
Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and disrupting peptidoglycan cross-linking. This leads to cell lysis and death primarily in susceptible gram-positive bacteria.
400 mg orally once daily for 5-10 days.
1-2 g IV/IM every 6-8 hours; maximum 12 g/day.
None Documented
None Documented
Clinical Note
moderateCefazolin + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Cefazolin."
Clinical Note
moderateCefazolin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefazolin."
Clinical Note
moderateCefazolin + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefazolin."
Clinical Note
moderatePhenytoin + Cefazolin
Terminal elimination half-life: 2.6-3.0 hours; prolonged in renal impairment (up to 10-15 hours in severe impairment)
1.8 hours in normal renal function; extends to 30–70 hours in end-stage renal disease (CrCl <10 mL/min).
Renal: 92-96% unchanged; biliary/fecal: <5%
Renal: 80–90% unchanged via glomerular filtration and tubular secretion; biliary: <1%; fecal: negligible.
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"The protein binding of Cefazolin can be decreased when combined with Phenytoin."